Multiple Sclerosis (MS) is a chronic, inflammatory disease affecting the central nervous system. Diagnosis and treatment decisions for people with MS (PwMS) rely on clinical assessments, imaging, and body fluid evaluations. However, the current methods provide limited predictive value for individualizing treatments. Emerging digital measures, like the dreaMS software program developed by the Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) in collaboration with Indivi, aim to offer more granular, continuous, and remote monitoring of disease progression. These digital tools are embedded in a mobile app and have shown promise in generating digital biomarkers (DB) that may enhance traditional MS assessments.

The DreaMS VS1 study is an international research project designed to validate the digital biomarkers generated through the dreaMS software. It includes 300-400 PwMS and assesses the clinical validity of candidate digital biomarkers (cDB) related to movement, balance, dexterity, vision, and cognition.

The main objective of the DreaMS VS1 study is to provide validated digital biomarkers that can be used for patient care, research, and regulatory decisions related to MS treatment. Beyond validation, the study aims to create a collaborative research platform for future studies and international academic partnerships. This research will contribute to more precise MS monitoring and treatment, improving the quality of life for PwMS by leveraging advanced digital health technologies.